194 related articles for article (PubMed ID: 23411609)
1. Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes.
Friedrich C; Emser A; Woerle HJ; Graefe-Mody U
Am J Ther; 2013; 20(6):618-21. PubMed ID: 23411609
[TBL] [Abstract][Full Text] [Related]
2. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
Barnett AH
Adv Ther; 2011 Jun; 28(6):447-59. PubMed ID: 21603986
[TBL] [Abstract][Full Text] [Related]
3. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*).
Graefe-Mody U; Friedrich C; Port A; Ring A; Retlich S; Heise T; Halabi A; Woerle HJ
Diabetes Obes Metab; 2011 Oct; 13(10):939-46. PubMed ID: 21672124
[TBL] [Abstract][Full Text] [Related]
4. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
5. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).
Scheen AJ
Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1561-76. PubMed ID: 22022857
[TBL] [Abstract][Full Text] [Related]
6. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
[TBL] [Abstract][Full Text] [Related]
7. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.
Deacon CF; Holst JJ
Expert Opin Investig Drugs; 2010 Jan; 19(1):133-40. PubMed ID: 19947894
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
Graefe-Mody EU; Padula S; Ring A; Withopf B; Dugi KA
Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
Heise T; Graefe-Mody EU; Hüttner S; Ring A; Trommeshauser D; Dugi KA
Diabetes Obes Metab; 2009 Aug; 11(8):786-94. PubMed ID: 19476474
[TBL] [Abstract][Full Text] [Related]
10. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
Forst T; Pfützner A
Expert Opin Pharmacother; 2012 Jan; 13(1):101-10. PubMed ID: 22149370
[TBL] [Abstract][Full Text] [Related]
11. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.
Friedrich C; Glund S; Lionetti D; Kissling CJ; Righetti J; Patel S; Graefe-Mody U; Retlich S; Woerle HJ
Br J Clin Pharmacol; 2013 Sep; 76(3):445-54. PubMed ID: 23331248
[TBL] [Abstract][Full Text] [Related]
13. Linagliptin (Tradjenta)--a new DPP-4 inhibitor for type 2 diabetes.
Med Lett Drugs Ther; 2011 Jun; 53(1367):49-50. PubMed ID: 21701440
[No Abstract] [Full Text] [Related]
14. Pharmacokinetics of linagliptin in subjects with hepatic impairment.
Graefe-Mody U; Rose P; Retlich S; Ring A; Waldhauser L; Cinca R; Woerle HJ
Br J Clin Pharmacol; 2012 Jul; 74(1):75-85. PubMed ID: 22242621
[TBL] [Abstract][Full Text] [Related]
15. Bioequivalence of Linagliptin 5 mg once daily and 2.5 mg twice daily: pharmacokinetics and pharmacodynamics in an open-label crossover trial.
Friedrich C; Jungnik A; Retlich S; Ring A; Meinicke T
Drug Res (Stuttg); 2014 May; 64(5):269-75. PubMed ID: 24154935
[TBL] [Abstract][Full Text] [Related]
16. Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Toth PP
Postgrad Med; 2011 Jul; 123(4):46-53. PubMed ID: 21680988
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.
Neumiller JJ
Ann Pharmacother; 2012 Mar; 46(3):358-67. PubMed ID: 22318932
[TBL] [Abstract][Full Text] [Related]
18. Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.
Groop PH; Del Prato S; Taskinen MR; Owens DR; Gong Y; Crowe S; Patel S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2014 Jun; 16(6):560-8. PubMed ID: 24612167
[TBL] [Abstract][Full Text] [Related]
19. Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):363-77. PubMed ID: 23373842
[TBL] [Abstract][Full Text] [Related]
20. Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.
Barnett AH
Expert Opin Drug Saf; 2015 Jan; 14(1):149-59. PubMed ID: 25351273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
